BMTCN REVIEW COURSE GRAFT VERSUS HOST DISEASEcmesyllabus.com/wp-content/uploads/2016/03/HemMalig2016Lectur… · GRAFT VERSUS HOST DISEASE Jennifer Peterson MSN, RN, BMTCN, OCN, WCC

Click to edit Master Presentation Date

GRAFT VERSUS HOST DISEASE

Jennifer Peterson MSN, RN, BMTCN, OCN, WCC

Professional Practice Leader

Hematology/Hematopoietic Stem Cell Transplant

Department of Clinical Practice and Professional Education

How the Experts Treat Hematologic Malignancies

Las Vegas, NV

March 10, 2016

BMTCN REVIEW COURSE

DISCLOSURES

No Disclosures

Objectives

• Discuss risk factors for graft versus host disease (GVHD)

• Review organ systems affected by acute graft versus host

disease (aGVHD)

• Review organ systems affected by chronic graft versus

host disease (cGVHD)

• Discuss prevention and treatment strategies for GVHD

Note: the primary reference source for this course is Ezzone, S. (2013) Hematopoietic stem cell transplantation: a manual for nursing practice.

Oncology Nursing Society, Pittsburgh, PA

INTRODUCTION

• GVHD is an immunologic reaction of the donor immune cells against the host tissues

• Historically, it was divided based on the timing of occurrence

• Acute – within the first 100 days

• Chronic – after first 100 days

• More often is divided based on clinical features

• Classic acute GVHD

• Persistent, recurrent, late onset acute GVHD

• Classic chronic GVHD

• Overlap GVHD: • Features of both

GVHD

• Remains poorly understood

• Leading cause of non-relapse mortality in allo HCT recipients

• Increased morbidity Impaired QOL

• Escalation and prolonged use of immune suppression Infections

• Organ dysfunction

• Common problem after allo HCT

• GVHD occurs in up to 40% of sibling donor recipients and up to 70% of unrelated donor recipients

• Chronic GVHD occurs in 50% of 3-month survivors after allo HCT

• Separating GVHD from GVL

• Has many implications

GVHD Prophylaxis

• REGIMENS:

• Calcineurin inhibitor (Tacrolimus/Cyclosporine) + MTX

• Tacrolimus + Sirolimus is another frequently used combination • Randomized study showed comparable efficacy to Tacro/Siro

• Cellcept-based regimen

• Post-transplant Cytoxan • Unique for haploidentical HCT

• The addition of mini-dose MTX, ATG & Velcade • Mismatch cases with lower likelihood of relapse

• DURATION:

• Started before day 0

• Continue for at least 3-6 months:

• Depends on donor source

• Risk of disease relapse

• Occurrence of GVHD

Risk Factors for Acute GVHD

• Degree of (HLA) mismatch • HLA-A, -B, -C, and –DRB

• Gender disparity and donor parity • Female to male

• Multiparity Maternal allo-immunization

• Age of donor and recipient

• Intensity of conditioning regimen • Reduce intensity vs. myeloablative

• Source of graft • Peripheral blood vs. marrow vs. cord

Acute GVHD

• Skin

• GI tract

• Liver

9

Acute GVHD

• Skin – Most common organ affected

– First to show symptoms

– Maculopapular rash often starting on palms and

soles

– Pt may complain of pain or itching to affected areas

– Usually correlates with engraftment; reduced intensity

have delayed onset of GVHD

– Rash becomes confluent as it progresses however,

blisters may form. Severe cases resemble burn

patients

• Differential diagnosis:

• Chemotherapy/radiation, drug, infection, engraftment

Acute GVHD

• GI tract • Upper GI: Nausea/vomiting, anorexia, weight loss

• Lower GI: Liquid diarrhea (may be bloody), abdominal

cramping, abdominal distension

• Differential diagnosis:

• Chemotherapy/radiation, medications, infections

Acute GVHD

• Liver • Increased bilirubin, alkaline phosphatase

• Transaminitis less common

• Differential diagnosis:

• Sinusoidal obstructive syndrome, infections, drug toxicities,

conditioning regimen effects, total parenteral nutrition, sepsis

Acute GVHD – Skin Presentation

Images used with permission: Elsevier Clinical Key © 2016

Grading of Acute Skin GVHD

Grade Description

I Rash <25% of body

II Rash 25% – 50% of body

III Generalized erythroderma or rash

>50% of body

IV Bullae formation and/or with

desquamation

Przepiorka D et al. Bone Marrow Transplant. 1995;15:825-8.

Grading of Acute Liver GVHD

Grade Description

I Bilirubin 2-3 mg/dL

II Bilirubin 3.1-6 mg/dL

III Bilirubin 6.1 – 15 mg/dL

IV Bilirubin > 15 mg/dL

Przepiorka D et al. Bone Marrow Transplant. 1995;15:825-8.

Grading of Acute Gut GVHD

Grade Description

I Diarrhea 500-1000 ml/day or persistent nausea,

vomiting or anorexia with biopsy proven upper GI

involvement

II Diarrhea 1000 - 1500 ml/day

III Diarrhea > 1500 mL/day

IV Severe abdominal pain with or without ileus or stool

with frank blood

Przepiorka D et al. Bone Marrow Transplant. 1995;15:825-8.

Overall Grade of Acute GVHD

Grade Skin Liver Gut

I I-II None None

II III I or I

III II-III or II-IV

IV IV IV

Przepiorka D et al. Bone Marrow Transplant. 1995;15:825-8.

Diagnosis of Acute GVHD

• Diagnosis is predominantly based on clinical findings &

exclusion of other causes

• Biopsy can be helpful for excluding other etiologies

• GI tract (EGD, flex sigmoidoscopy)

• Skin biopsy

• Not very sensitive or specific

• Liver biopsy

• Done if etiology is not clear

• Transjugular approach is safer

Acute GVHD Treatment

• Initiated once GVHD is suspected or confirmed

• Corticosteroid remains the standard first line therapy

• Randomized studies failed to show benefit of combining other agents

• Starting Solu-Medrol dose 1-2mg/Kg

• 10mg/kg was not superior to 2mg/kg

• 1mg/kg might be enough for grade II disease

• Grade I skin GVHD • Managed with topical therapy + optimizing immunosuppression

levels

• Non-absorbable steroid are very useful adjuvant therapy in GI GVHD

• Survival correlates directly with the response to initial therapy

Salvage Therapy for Steroid Resistant aGVHD

• m-TOR inhibitor- • Sirolimus

• Extracorporeal photopheresis (ECP)

• Anti-TNF antibodies- • Infliximab, Etanercept

• Infliximab: Begin gtt within 3 hrs from preparation, and infuse at least over 2hrs. Risk of hypersensitivity reaction. Monitor vital signs closely

• Cellcept

• IL2 inhibitors- • Basiliximab

• Hypersensitivity reaction, monitor vital sign

• Nucleoside analogues- Pentostatin • Infuse over 15 minutes, and pre-infusion hydration is given usually

• Rituximab • Infused over 4 hrs, and associated with risk of hypersensitivity reaction

Topical Agents for Cutaneous GVHD

• Topical Steroids

• Different potency

• Triamcinolone acetone 0.1% cream

• Apply twice daily

• Do not use on face

• Calcineurin inhibitors:

• Tacrolimus cream 0.03% or 0.1%

• Apply twice daily

Refractory aGVHD

• Steroid refractory defined as

• GVHD progression after 3 days of therapy

• No improvement in 1 week of therapy

• No resolution in 2 weeks of therapy

• Second-line treatment characterized by

1. High failure rate

2. Significant toxicities

3. Poor survival

• No standard of care for second or beyond therapy

• No data for efficacy for one regimen over another

22

Nursing Management :Acute GVHD

Skin

• Skin cleansing

• Moisturize skin/Avoid drying lotions

• Topical antihistamines

• Topical steroids

• Analgesics

• Maintain mobility with passive Range of Motion (ROM)

• Educate patient to avoid sun exposure and dehydration

23

Nursing Management: Acute GVHD

Gut

• Maintain fluid and electrolyte balance

• Sitz baths for comfort

• Prevent rectal fissures

• Administer platelets as needed/ordered

• Nutritional support

• Protective barrier on rectal area

Chronic GVHD

• Pathophysiology of chronic GVHD not well understood

• Leading cause of non-relapse related mortality for patients > 2 yrs post allogeneic transplant

• Associated with: • Decreased quality of life

• Impaired functional status

• Ongoing need for immunosuppressive medications

• Risk factors • History of acute GVHD

• Similar factors for acute GVHD

• Infusion of DLI for treatment of recurrent disease

25

Chronic GVHD

Increased incidence due to:

• History of acute GVHD

• Mismatched donor

• Older recipient age

• Use of peripheral blood as stem cell source

• Infusion of donor lymphocytes for treatment of recurrent malignancy

Signs and Symptoms of cGVHD

Filipovich AH et . Biol Blood Marrow Transplant.

2005;11:945-56. Socie G et al. Blood. 2014;124:374-84.

Skin Changes

Images used with permission: Elsevier Clinical Key © 2016

Oral Manifestations of cGVHD

Lichenoid changes Mucocele

Images used with permission: Elsevier Clinical Key © 2016

NIH scoring for cGVHD

Organ/site grading

0 No involvement

1 (Mild) No significant impairment

2 (Moderate) Significant impairment of daily activity

3 (Severe) Major disability

Overall grading

Mild One or two involved organs with a score of 1 and no

pulmonary involvement

Moderate Involvement of 3 organs with a score of 1, at least one

organ with a score 2 or pulmonary GVHD with a score 1

Severe Score of 3 in any organ or site or patient who have

pulmonary GVHD scoring 2 or 3

Filipovich AH et . Biol Blood Marrow Transplant.

2005;11:945-56. .

Treatment for cGVHD

• Infection is leading cause of death for patients with chronic GVHD

• Patient education is essential

• Prophylaxis treatment

• Viral and pneumocystis pneumonia prophylaxis should be continued while on immunosuppression

• Mold prophylaxis should be given for patients on prolonged high dose steroid

• Patients should receive prophylaxis antibiotics prior to dental procedures to prevent endocarditis

• Monitor for CMV infection closely

• Revaccination after 6-12 months of HCT and after stopping IS

• IVIG replacement for hypogammaglobulinemia

Treatment for cGVHD

• Mild cGVHD

• May not require treatment

• Wait and watch

• Severe cGVHD

• Topical agents

• Systemic agents

• Prednisone is first line treatment at doses 0.5-1mg/kg

• No consensus on second line therapy

• Extracorporeal photopheresis

• Supportive care

Organ-specific management and

supportive care in cGVHD

• Cutaneous

• Topical therapy – steroid or topical calcineurin inhibitors • Regular moisturizers for xerosis • Annual skin check by dermatologist

• Increased risk of skin cancer • ECP is effective in skin GVHD • Physiotherapy for scleroderma like cases

• Ocular

• Artificial tears • Lubrication • Topical anti-inflammatory (steroid/cyclosporine emulsion) treatment • Referral to specialist for change in vision • Occlusive eyewear to prevent evaporation

• Oral

• Dexamethasone elixir • Artificial saliva • Salivary stimulants • Adequate hydration

Organ-specific management and supportive

care in cGVHD

• GI

• Topical steroid

• Optimizing nutrition

• Genital • High potency topical steroid (female)

• Use of dilators

• Early referral to specialist in difficult cases

• Lungs • Prophylactic antimicrobial therapy

• Oxygen

• Inhaled steroid/immunosuppressants